Anti‐oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient‐derived tumor xenograft model

BACKGROUND: Aberrant expression of decoy receptor 3 (DcR3) is considered to be a diagnostic and therapeutic target for human cancers. The aim of this study was to assess DcR3 as a target of the anticancer effects of triptolide (TPL) in preclinical patient‐derived tumor xenograft (PDTX) models of ora...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Cheng‐Yu, Lin, Chih‐Kung, Hsieh, Cheng‐Chih, Tsao, Chang‐Huei, Lin, Chun‐Shu, Peng, Bo, Chen, Yen‐Tzu, Ting, Chun‐Chieh, Chang, Wei‐Chin, Lin, Gu‐Jiun, Sytwu, Huey‐Kang, Chen, Yuan‐Wu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590365/
https://www.ncbi.nlm.nih.gov/pubmed/30537218
http://dx.doi.org/10.1002/hed.25554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590365/
https://www.ncbi.nlm.nih.gov/pubmed/30537218
http://dx.doi.org/10.1002/hed.25554

Ejemplares similares